US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

bioAffinity Technologies, Inc.

0.3800

-0.0685-15.27%

Post-market: 0.3700-0.0100-2.63%19:57 EDT

Volume:333.89K

Turnover:133.71K

Market Cap:6.80M

PE:-0.51

High:0.4400

Open:0.4400

Low:0.3601

Close:0.4485

Loading ...

Overview Company News Filings

Press Release: WallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

Zacks Initiates Coverage of bioAffinity With Neutral Recommendation

The Zacks Analyst Blog Highlights Amazon, Bank of America, Caterpillar, NVE and bioAffinity

Top Research Reports for Amazon.com, Bank of America & Caterpillar

BioAffinity Technologies Says Australian Patent Office Accepts Lung Cancer Test Application

MT Newswires Live

BRIEF-Bioaffinity Technologies Announces Acceptance Of Patent Application For Early-Stage Lung Cancer Diagnostic

bioAffinity Technologies Inc - Australian Patent for Cypath Lung Test to Expire in 2042

THOMSON REUTERS

bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic

THOMSON REUTERS

bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic

bioAffinity Technologies Boosts Sales with CyPath Lung

bioAffinity Technologies Reports $2.4M Revenue For Q3 2024; Expanded CyPath Lung Test Sales To Physicians In Illinois, Alabama, And Louisiana; Now Receiving Orders From Physicians In 11 States

bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024

THOMSON REUTERS

bioAffinity Technologies Inc Qtrly EPS $-0.16

THOMSON REUTERS

Press Release: bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024

BRIEF-BioAffinity Technologies Appoints New Chief Science Officer To Spearhead Product Development

BioAffinity Technologies appoints William Bauta, Ph.D. Chief Science Officer

bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development

THOMSON REUTERS

bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BIAF/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BIAF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIAF\",,,,,undefined,":{"symbol":"BIAF","market":"US","secType":"STK","nameCN":"bioAffinity Technologies, Inc.","latestPrice":0.38,"timestamp":1746475200000,"preClose":0.4485,"halted":0,"volume":333889,"hourTrading":{"tag":"盘后","latestPrice":0.37,"preClose":0.38,"latestTime":"19:57 EDT","volume":27954,"amount":10524.03555,"timestamp":1746489423190},"delay":0,"floatShares":13118699,"shares":17906767,"eps":-0.745551,"marketStatus":"Closed","change":-0.0685,"latestTime":"05-05 16:00:00 EDT","open":0.44,"high":0.44,"low":0.3601,"amount":133713.77657486,"amplitude":0.178149,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.745551,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746518400000},"marketStatusCode":5,"adr":0,"listingDate":1662004800000,"exchange":"NASDAQ","adjPreClose":0.4485,"preHourTrading":{"tag":"盘前","latestPrice":0.4484,"preClose":0.4485,"latestTime":"08:17 EDT","volume":457,"amount":202.78350406,"timestamp":1746447479012},"postHourTrading":{"tag":"盘后","latestPrice":0.37,"preClose":0.38,"latestTime":"19:57 EDT","volume":27954,"amount":10524.03555,"timestamp":1746489423190},"volumeRatio":1.832473},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BIAF\",,,,,undefined,":{"symbol":"BIAF","floatShares":13118699,"roa":"-75.95%","roe":"-242.44%","lyrEps":-0.745551,"volumeRatio":1.832473,"shares":17906767,"dividePrice":0,"high":0.44,"amplitude":0.178149,"preClose":0.4485,"low":0.3601,"week52Low":0.2404,"pbRate":"2.62","psRate":"0.73","week52High":2.9893,"institutionHeld":0,"latestPrice":0.38,"eps":-0.745551,"divideRate":0,"volume":333889,"delay":0,"ttmEps":-0.745551,"open":0.44,"prevYearClose":0.91,"prevWeekClose":0.4485,"prevMonthClose":0.47,"prevQuarterClose":0.26,"fiveDayClose":0.4698,"twentyDayClose":0.6834,"sixtyDayClose":0.84},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BIAF\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514019347","title":"Press Release: WallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514019347","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514019347?lang=en_us&edition=fundamental","pubTime":"2025-02-26 00:05","pubTimestamp":1740499500,"startTime":"0","endTime":"0","summary":"WallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million. The closing of the offering is expected to occur on or about February 26, 2025, subject to the satisfaction of customary closing conditions. The gross proceeds from the warrant inducement are expected to be approximately $1.4 million, excluding any proceeds that may be received upon the exercise of the  New Warrants and before deducting placement agent fees and other offering expenses payable by the Company.WallachBeth Capital is acting as sole placement agent for the for the warrant inducement transaction.This press release contains forward-looking statements, including statements regarding the anticipated exercise of","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAF","BK4139"],"gpt_icon":0},{"id":"2514184460","title":"bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514184460","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514184460?lang=en_us&edition=fundamental","pubTime":"2025-02-25 22:58","pubTimestamp":1740495480,"startTime":"0","endTime":"0","summary":"SAN ANTONIO, February 25, 2025----bioAffinity Technologies, Inc.  announced today it has entered into warrant exercise agreements with three existing accredited investors to exercise certain outstanding warrants to purchase an aggregate of 2,438,473 of the Company’s shares of common stock . In consideration for the immediate exercise in full of the Existing Warrants for gross cash proceeds of approximately $1.4 million, the exercising holders will receive in a private placement new unregistered warrants  to purchase up to an aggregate of 2,926,168 shares of common stock  with an exercise price of $0.85 per share. The New Warrants are initially exercisable on the date that stockholder approval of the exercise of the New Warrants is obtained and will expire five years from the date of such approval. In connection with the exercise of the Existing Warrants, the Company agreed to reduce the exercise price of the Existing Warrants from $1.50 to $0.58 per share. The exercise of the Existing ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioaffinity-technologies-announces-warrant-inducement-145800942.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BIAF","BIAFW"],"gpt_icon":0},{"id":"2509209192","title":"Zacks Initiates Coverage of bioAffinity With Neutral Recommendation","url":"https://stock-news.laohu8.com/highlight/detail?id=2509209192","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509209192?lang=en_us&edition=fundamental","pubTime":"2025-02-06 23:36","pubTimestamp":1738856160,"startTime":"0","endTime":"0","summary":"Zacks Investment Research has recently initiated coverage of bioAffinity Technologies, Inc. BIAF, assigning a \"Neutral\" recommendation to the company's shares. This assessment comes amid a mixed outlook for the company, which has been making notable strides in the lung cancer diagnostics space despite industry challenges.BIAF, headquartered in San Antonio, TX, develops non-invasive diagnostics for detecting early-stage lung cancer and other lung diseases. The company is also advancing research into potential therapeutic treatments for various cancers.bioAffinity’s commercial diagnostic test, CyPath Lung, has seen a 1,300% increase in orders in the first nine months of 2024, propelling third-quarter revenues to $2.4 million, compared to just $0.3 million in the prior-year period. The company has expanded sales into 11 states, secured Federal Supply Schedule inclusion, and successfully completed a Texas pilot program, reinforcing its potential for broader adoption across government healt","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zacks-initiates-coverage-bioaffinity-neutral-153600182.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BIAF","BIAFW"],"gpt_icon":0},{"id":"2509222644","title":"The Zacks Analyst Blog Highlights Amazon, Bank of America, Caterpillar, NVE and bioAffinity","url":"https://stock-news.laohu8.com/highlight/detail?id=2509222644","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509222644?lang=en_us&edition=fundamental","pubTime":"2025-02-06 18:34","pubTimestamp":1738838040,"startTime":"0","endTime":"0","summary":"Chicago, IL – February 6, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amazon.com, Inc. AMZN, Bank of America Corp. BAC, Caterpillar Inc. CAT, NVE Corp. NVEC and bioAffinity Technologies, Inc. BIAF.Here are highlights from Wednesday’s Analyst Blog:. Top Research Reports for Amazon, Bank of America and Caterpillar. The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc., Bank of America Corp. and Caterpillar Inc., as well as two micro-cap stocks NVE Corp. and bioAffinity Technologies, Inc. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.Shares of Bank of America ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zacks-analyst-blog-highlights-amazon-103400055.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0306807586.USD","LU0494093205.USD","LU0158827948.USD","LU1803068979.SGD","NVEC","USAW.SI","IE00BJTD4N35.SGD","BIAFW","LU0276348264.USD","AMZN","LU0056508442.USD","LU0029864427.USD","IE00B3SWFQ91.USD","LU0320765059.SGD","IE00BKVL7J92.USD","LU2326559502.SGD","LU1074936037.SGD","LU2357305700.SGD","LU2452424414.USD","IE00BYQQ9H92.USD","LU0061475181.USD","BK4548","LU0823434583.USD","LU2077746001.SGD","LU2236285917.USD","LU0310799852.SGD","LU2471134523.USD","LU1037948897.HKD","IE0002270589.USD","LU0170899867.USD","BAC","LU2250418816.HKD","IE00B19Z3581.USD","IE00BMPRXN33.USD","LU1804176565.USD","LU1988902786.USD","LU0096362180.USD","LU0302445910.USD","LU2211815571.USD","CAT","BIAF","LU0321505868.SGD","LU1989764664.SGD","LU0345769631.USD","LU2087621335.USD","LU1629891620.HKD","LU1791710582.SGD","IE0009G5SDU7.USD","LU2065171402.SGD","BK4533","BK4561"],"gpt_icon":1},{"id":"2509266597","title":"Top Research Reports for Amazon.com, Bank of America & Caterpillar","url":"https://stock-news.laohu8.com/highlight/detail?id=2509266597","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509266597?lang=en_us&edition=fundamental","pubTime":"2025-02-06 06:11","pubTimestamp":1738793460,"startTime":"0","endTime":"0","summary":"Wednesday, February 5, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/top-research-reports-amazon-com-221100889.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0648000940.SGD","LU0070302665.USD","BIAF","LU0211327993.USD","AMZN","IE0004445015.USD","IE00B775SV38.USD","LU0130102774.USD","LU0345768740.USD","LU0943347566.SGD","LU1880398471.USD","LU0211328371.USD","SG9999015952.SGD","BIAFW","IE00BLSP4452.SGD","LU1791807156.HKD","BAC","LU0154236417.USD","LU0149725797.USD","LU2602419157.SGD","LU1496350171.SGD","LU1914381329.SGD","CAT","LU2362541273.HKD","LU0823421416.USD","IE00BKDWB100.SGD","IE00BFSS8Q28.SGD","LU0965508806.USD","LU1935042991.SGD","CVX","LU2133065610.SGD","LU0321505868.SGD","LU2456880835.USD","NVEC","SG9999015978.USD","IE00B3CCJ963.GBP","LU2065170008.USD","LHX","IE0009356076.USD","LU0353189763.USD","LU0965509010.AUD","BK4201","LU1852331112.SGD","BK4504","LU1267930573.SGD","LU2213496289.HKD","LU0198837287.USD","USAW.SI","NUE","LU1720051017.SGD","IE0003U64NQ7.SGD"],"gpt_icon":1},{"id":"2505077611","title":"BioAffinity Technologies Says Australian Patent Office Accepts Lung Cancer Test Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2505077611","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505077611?lang=en_us&edition=fundamental","pubTime":"2025-01-23 01:32","pubTimestamp":1737567156,"startTime":"0","endTime":"0","summary":"BioAffinity Technologies  said the Australian patent office accepted its patent application for the method used in the CyPath Lung diagnostic test for predicting lung cancer.The Australian patent, expected to be issued in three months, will expire in 2042 and will be the second patent for the CyPath Lung test, the company said Wednesday in a statement.Price: 0.68, Change: +0.01, Percent Change: +2.09","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XAO.AU","XJO.AU","BIAF","BK4139","XKO.AU"],"gpt_icon":0},{"id":"2505885725","title":"BRIEF-Bioaffinity Technologies Announces Acceptance Of Patent Application For Early-Stage Lung Cancer Diagnostic","url":"https://stock-news.laohu8.com/highlight/detail?id=2505885725","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505885725?lang=en_us&edition=fundamental","pubTime":"2025-01-22 22:22","pubTimestamp":1737555732,"startTime":"0","endTime":"0","summary":"BRIEF-Bioaffinity Technologies Announces Acceptance Of Patent Application For Early-Stage Lung Cancer DiagnosticJan 22 (Reuters) - bioAffinity Technologies Inc BIAF.O:BIOAFFINITY TECHNOLOGIES ANNOUNCE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nTUA1HNTGP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAFW","BK4139","BIAF"],"gpt_icon":0},{"id":"2505874421","title":"bioAffinity Technologies Inc - Australian Patent for Cypath Lung Test to Expire in 2042","url":"https://stock-news.laohu8.com/highlight/detail?id=2505874421","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505874421?lang=en_us&edition=fundamental","pubTime":"2025-01-22 21:00","pubTimestamp":1737550804,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nTUA1HNTGP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIAF","BK4139","BIAFW"],"gpt_icon":0},{"id":"2505687744","title":"bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic","url":"https://stock-news.laohu8.com/highlight/detail?id=2505687744","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505687744?lang=en_us&edition=fundamental","pubTime":"2025-01-22 21:00","pubTimestamp":1737550804,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nTUA1HNTGP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BIAF","BIAFW"],"gpt_icon":0},{"id":"2505074201","title":"bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic","url":"https://stock-news.laohu8.com/highlight/detail?id=2505074201","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505074201?lang=en_us&edition=fundamental","pubTime":"2025-01-22 21:00","pubTimestamp":1737550800,"startTime":"0","endTime":"0","summary":"SAN ANTONIO, January 22, 2025----bioAffinity Technologies, Inc. , a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced that the Australian Patent Office , has accepted bioAffinity’s patent application for the method of predicting the likelihood of lung cancer used by the CyPath Lung diagnostic test for early-stage lung cancer.bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath Lung is marketed","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioaffinity-technologies-announces-acceptance-patent-130000678.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SSI","BIAFW","BIAF"],"gpt_icon":0},{"id":"2493523462","title":"bioAffinity Technologies Boosts Sales with CyPath Lung","url":"https://stock-news.laohu8.com/highlight/detail?id=2493523462","media":"TipRanks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493523462?lang=en_us&edition=fundamental","pubTime":"2024-12-21 19:33","pubTimestamp":1734780791,"startTime":"0","endTime":"0","summary":"Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks. bioAffinity Technologies, Inc. reports a successful year in 2024, significantly boosting sales and operations through its lung cancer detection product, CyPath Lung. The company plans to expand its market presence in 2025, leveraging its growth in the U.S. healthcare system and focusing on key regions and markets, including the VA and military sectors, to further increase the accessibility and adoption of its test.bioAffinity Technologies, Inc. operates in the medical diagnostics industry, focusing on the early detection of lung cancer through its noninvasive test, CyPath Lung. The company aims to address the critical need for early cancer detection, holding patents in the U.S., the European Union, and Asia, with a significant market presence in these regions.See more data about BIAF stock on TipRanks’ Stock Analysis page.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/mZDcjNmmKhClNQkla1p5GA--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/d622151edd421d0d1465b02718e80caa","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/mZDcjNmmKhClNQkla1p5GA--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/d622151edd421d0d1465b02718e80caa"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/bioaffinity-technologies-boosts-sales-cypath-113311538.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioaffinity-technologies-boosts-sales-cypath-113311538.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BIAFW","BIAF"],"gpt_icon":0},{"id":"2483487073","title":"bioAffinity Technologies Reports $2.4M Revenue For Q3 2024; Expanded CyPath Lung Test Sales To Physicians In Illinois, Alabama, And Louisiana; Now Receiving Orders From Physicians In 11 States","url":"https://stock-news.laohu8.com/highlight/detail?id=2483487073","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483487073?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:20","pubTimestamp":1731590437,"startTime":"0","endTime":"0","summary":"Expanded CyPath® Lung test sales to physicians in Illinois, Alabama, and Louisiana; now receiving orders from physicians in 11 statesNumber of physician offices signed increased 75% over Q2 2024Reaffirmed $9.6","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41971030/bioaffinity-technologies-reports-2-4m-revenue-for-q3-2024-expanded-cypath-lung-test-sales-to-physic","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"bioAffinity Technologies Reports $2.4M Revenue For Q3 2024; Expanded CyPath Lung Test Sales To Physicians In Illinois, Alabama, And Louisiana; Now Receiving Orders From Physicians In 11 States","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAF"],"gpt_icon":0},{"id":"2483877805","title":"bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483877805","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483877805?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:00","pubTimestamp":1731589205,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nTUA623Y9J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIAF","BK4139","BIAFW"],"gpt_icon":0},{"id":"2483877209","title":"bioAffinity Technologies Inc Qtrly EPS $-0.16","url":"https://stock-news.laohu8.com/highlight/detail?id=2483877209","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483877209?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:00","pubTimestamp":1731589205,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nTUA623Y9J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BIAF"],"gpt_icon":0},{"id":"2483087743","title":"Press Release: bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483087743","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483087743?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:00","pubTimestamp":1731589200,"startTime":"0","endTime":"0","summary":"Expanded CyPath Lung test sales to physicians in Illinois, Alabama, and Louisiana; now receiving orders from physicians in 11 states. Number of physician offices signed increased 75% over Q2 2024. Reaffirmed $9.6 million 2024 revenue forecast for wholly owned Precision Pathology subsidiary. bioAffinity Technologies, Inc. , a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the three months ended September 30, 2024.Generated quarterly revenue of $2.4 million in the third quarter of. More than 1,300% growth rate for CyPath Lung orders in first nine. Number of physician offices signed increased by 75% compared to the. second quarter of 2024, setting the stage for acceleration of CyPath. Lung through 1,380 government health care facilities. Approximately 8,000. Referrals and word-of-mouth from physicians, including key opinion. in states beyond Texas; now rece","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIAF"],"gpt_icon":0},{"id":"2480199589","title":"BRIEF-BioAffinity Technologies Appoints New Chief Science Officer To Spearhead Product Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2480199589","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480199589?lang=en_us&edition=fundamental","pubTime":"2024-11-04 22:32","pubTimestamp":1730730776,"startTime":"0","endTime":"0","summary":"Nov 4 (Reuters) - bioAffinity Technologies Inc   :   * BIOAFFINITY TECHNOLOGIES APPOINTS NEW CHIEF SCIENCE OFFICER TO SPEARHEAD PRODUCT DEVELOPMENTSource text:    Further company coverage:    (Reuters.Briefs@thomsonreuters.com)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIAF"],"gpt_icon":0},{"id":"2480004300","title":"BioAffinity Technologies appoints William Bauta, Ph.D. Chief Science Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2480004300","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480004300?lang=en_us&edition=fundamental","pubTime":"2024-11-04 21:15","pubTimestamp":1730726150,"startTime":"0","endTime":"0","summary":"bioAffinity Technologies (BIAF) announced that William Bauta, Ph.D., has been appointed Chief Science Officer. Before joining bioAffinity in 2016 a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bioaffinity-technologies-appoints-william-bauta-ph-d-chief-science-officer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bioaffinity-technologies-appoints-william-bauta-ph-d-chief-science-officer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BIAF"],"gpt_icon":0},{"id":"2480307080","title":"bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2480307080","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480307080?lang=en_us&edition=fundamental","pubTime":"2024-11-04 21:00","pubTimestamp":1730725204,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241104:nTUA6KCG94:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BIAFW","BIAF"],"gpt_icon":0},{"id":"2480588187","title":"bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2480588187","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480588187?lang=en_us&edition=fundamental","pubTime":"2024-11-04 21:00","pubTimestamp":1730725200,"startTime":"0","endTime":"0","summary":"Dr. William Bauta, bioAffinity Senior Vice President of Research and Development and former Associate Director of Science at Genzyme and Ilex, steps into new role with the retirement of Dr. Vivienne Rebel. Dr. Bauta is responsible for multiple Company inventions and patents supporting bioAffinity’s diagnostic and therapeutic advancements, including improvements to optimize CyPath Lung, the Company’s noninvasive test to detect early-stage lung cancer, that both improved performance and cut costs. His discoveries have expanded the Company’s patent portfolio and added to a growing list of publications. In addition to bioAffinity patents on which he is a named inventor, he holds multiple healthcare-related patents and has published in more than a dozen scientific journals, including the journal Science.CyPath Lung uses proprietary advanced flow cytometry and artificial intellig","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ItQNjwTTpvwFz.E3ehvRPQ--~B/aD0yMDE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a8127d65ac48654886d55d2de9741a0a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ItQNjwTTpvwFz.E3ehvRPQ--~B/aD0yMDE7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a8127d65ac48654886d55d2de9741a0a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bioaffinity-technologies-appoints-chief-science-130000876.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BIAFW","BIAF"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":39,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BIAF\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-31","symbol":"BIAF","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"post","actualEps":-0.21},{"market":"US","date":"2024-05-15","symbol":"BIAF","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"pre","actualEps":-0.21},{"market":"US","date":"2024-04-01","symbol":"BIAF","fiscalQuarterEnding":"2023/12","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1711944000000,"reportTimeType":"pre","actualEps":-0.26},{"market":"US","date":"2023-11-14","symbol":"BIAF","fiscalQuarterEnding":"2023/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1699938000000,"reportTimeType":"post","actualEps":-0.26},{"market":"US","date":"2022-06-24","symbol":"BIAF","defaultRemindTime":1656077400000,"type":"split","dateTimestamp":1656043200000,"forFactor":1000000,"toFactor":142857,"ratio":7.000007000007}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BIAF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BIAF\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1743566400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BIAF\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BIAF","date":"2025-05-02","current":-0.940915,"percent":0.955556,"low":-7.049629,"twenty":-2.678705,"median":-1.937447,"eighty":-1.312067,"high":-0.479749,"avg":-2.047602,"sd":0.825949,"marketCap":8505714},"quantilePoints":[{"date":"2022-06-24","current":-2.566585,"twenty":-2.566585,"median":-2.566585,"eighty":-2.566585,"marketCap":18177210},{"date":"2022-06-27","current":-2.566585,"twenty":-2.566585,"median":-2.566585,"eighty":-2.566585,"marketCap":18177210},{"date":"2022-08-11","current":-2.358916,"twenty":-2.566585,"median":-2.358916,"eighty":-2.358916,"marketCap":16706445},{"date":"2022-09-02","current":-5.987938,"twenty":-4.619397,"median":-2.46275,"eighty":-2.358916,"marketCap":51799882},{"date":"2022-09-09","current":-4.059907,"twenty":-4.863395,"median":-3.313246,"eighty":-2.358916,"marketCap":35121054},{"date":"2022-09-16","current":-3.652217,"twenty":-4.741088,"median":-3.89853,"eighty":-2.40045,"marketCap":31594254},{"date":"2022-09-23","current":-1.792135,"twenty":-4.487981,"median":-3.376177,"eighty":-2.358916,"marketCap":15503227},{"date":"2022-09-30","current":-2.471617,"twenty":-4.114265,"median":-2.819851,"eighty":-2.358916,"marketCap":21381227},{"date":"2022-10-07","current":-2.505591,"twenty":-4.053112,"median":-2.557322,"eighty":-2.358916,"marketCap":21675127},{"date":"2022-10-14","current":-2.225304,"twenty":-4.000452,"median":-2.497097,"eighty":-2.347154,"marketCap":19250452},{"date":"2022-10-21","current":-2.216811,"twenty":-3.849267,"median":-2.475863,"eighty":-2.347154,"marketCap":19176977},{"date":"2022-10-28","current":-2.378188,"twenty":-3.625038,"median":-2.463123,"eighty":-2.315336,"marketCap":20573002},{"date":"2022-11-04","current":-2.233798,"twenty":-3.460264,"median":-2.45463,"eighty":-2.315336,"marketCap":19323927},{"date":"2022-11-11","current":-2.403668,"twenty":-3.212252,"median":-2.420656,"eighty":-2.252484,"marketCap":20793427},{"date":"2022-11-18","current":-1.777191,"twenty":-3.05767,"median":-2.378188,"eighty":-2.225304,"marketCap":21426560},{"date":"2022-11-25","current":-1.80496,"twenty":-2.819851,"median":-2.378188,"eighty":-2.131876,"marketCap":21761350},{"date":"2022-12-02","current":-2.040993,"twenty":-2.666968,"median":-2.361201,"eighty":-1.922976,"marketCap":24607065},{"date":"2022-12-09","current":-1.402315,"twenty":-2.566585,"median":-2.358916,"eighty":-1.874381,"marketCap":16906895},{"date":"2022-12-16","current":-1.367604,"twenty":-2.566585,"median":-2.344214,"eighty":-1.832728,"marketCap":16488407},{"date":"2022-12-23","current":-1.284298,"twenty":-2.548059,"median":-2.305993,"eighty":-1.80496,"marketCap":15484037},{"date":"2022-12-30","current":-1.110745,"twenty":-2.514085,"median":-2.255032,"eighty":-1.798929,"marketCap":13391600},{"date":"2023-01-06","current":-1.110745,"twenty":-2.500495,"median":-2.242292,"eighty":-1.623075,"marketCap":13391600},{"date":"2023-01-13","current":-1.152467,"twenty":-2.486905,"median":-2.225304,"eighty":-1.388472,"marketCap":13894621},{"date":"2023-01-20","current":-1.055207,"twenty":-2.476713,"median":-2.174343,"eighty":-1.310679,"marketCap":12722020},{"date":"2023-01-27","current":-1.994133,"twenty":-2.468219,"median":-2.120828,"eighty":-1.310679,"marketCap":24042106},{"date":"2023-02-03","current":-1.652232,"twenty":-2.463123,"median":-2.040993,"eighty":-1.338447,"marketCap":19920005},{"date":"2023-02-10","current":-1.423211,"twenty":-2.459726,"median":-1.972439,"eighty":-1.375935,"marketCap":17158824},{"date":"2023-02-17","current":-1.430084,"twenty":-2.45463,"median":-1.922976,"eighty":-1.388459,"marketCap":17241685},{"date":"2023-02-24","current":-1.249588,"twenty":-2.45463,"median":-1.909092,"eighty":-1.350943,"marketCap":15065550},{"date":"2023-03-03","current":-1.214877,"twenty":-2.449534,"median":-1.839671,"eighty":-1.294017,"marketCap":14647062},{"date":"2023-03-10","current":-1.062149,"twenty":-2.42745,"median":-1.832728,"eighty":-1.249588,"marketCap":12805717},{"date":"2023-03-17","current":-1.166282,"twenty":-2.417258,"median":-1.815373,"eighty":-1.209323,"marketCap":14061180},{"date":"2023-03-24","current":-1.270414,"twenty":-2.398572,"median":-1.80496,"eighty":-1.202381,"marketCap":15316642},{"date":"2023-03-31","current":-1.312067,"twenty":-2.378188,"median":-1.80496,"eighty":-1.207935,"marketCap":15818827},{"date":"2023-04-06","current":-1.847601,"twenty":-2.378188,"median":-1.802794,"eighty":-1.200992,"marketCap":15065550},{"date":"2023-04-14","current":-1.652577,"twenty":-2.378188,"median":-1.800628,"eighty":-1.207935,"marketCap":13475297},{"date":"2023-04-21","current":-1.888933,"twenty":-2.378188,"median":-1.802794,"eighty":-1.207935,"marketCap":15402574},{"date":"2023-04-28","current":-2.034236,"twenty":-2.369694,"median":-1.80496,"eighty":-1.214877,"marketCap":16587387},{"date":"2023-05-05","current":-2.060629,"twenty":-2.361201,"median":-1.805752,"eighty":-1.214877,"marketCap":16802598},{"date":"2023-05-12","current":-1.945568,"twenty":-2.358916,"median":-1.818844,"eighty":-1.221819,"marketCap":15864382},{"date":"2023-05-18","current":-1.86888,"twenty":-2.358916,"median":-1.832728,"eighty":-1.232926,"marketCap":15352628},{"date":"2023-05-26","current":-1.991074,"twenty":-2.358916,"median":-1.839671,"eighty":-1.244034,"marketCap":16356443},{"date":"2023-06-01","current":-1.897743,"twenty":-2.358916,"median":-1.843636,"eighty":-1.249588,"marketCap":15589735},{"date":"2023-06-09","current":-2.001445,"twenty":-2.355976,"median":-1.86888,"eighty":-1.249588,"marketCap":16441633},{"date":"2023-06-16","current":-1.856262,"twenty":-2.342515,"median":-1.871631,"eighty":-1.249588,"marketCap":15248975},{"date":"2023-06-23","current":-1.794041,"twenty":-2.33572,"median":-1.857029,"eighty":-1.249588,"marketCap":14737837},{"date":"2023-06-30","current":-1.845892,"twenty":-2.315336,"median":-1.851932,"eighty":-1.249588,"marketCap":15163786},{"date":"2023-07-07","current":-1.928853,"twenty":-2.305144,"median":-1.856262,"eighty":-1.253753,"marketCap":15845304},{"date":"2023-07-14","current":-1.825151,"twenty":-2.276266,"median":-1.847601,"eighty":-1.26486,"marketCap":14993406},{"date":"2023-07-21","current":-1.866632,"twenty":-2.254183,"median":-1.846747,"eighty":-1.270414,"marketCap":15334165},{"date":"2023-07-28","current":-1.877002,"twenty":-2.250785,"median":-1.845892,"eighty":-1.273191,"marketCap":15419355},{"date":"2023-08-04","current":-1.835522,"twenty":-2.247388,"median":-1.846747,"eighty":-1.285686,"marketCap":15078596},{"date":"2023-08-11","current":-1.887373,"twenty":-2.232099,"median":-1.845892,"eighty":-1.294017,"marketCap":15504545},{"date":"2023-08-18","current":-1.62887,"twenty":-2.225304,"median":-1.842782,"eighty":-1.306513,"marketCap":16072062},{"date":"2023-08-24","current":-1.607329,"twenty":-2.225304,"median":-1.839463,"eighty":-1.312067,"marketCap":15859525},{"date":"2023-09-01","current":-1.53986,"twenty":-2.21851,"median":-1.835522,"eighty":-1.312067,"marketCap":15193808},{"date":"2023-09-08","current":-1.530959,"twenty":-2.199824,"median":-1.835522,"eighty":-1.314844,"marketCap":15105982},{"date":"2023-09-14","current":-1.44195,"twenty":-2.182837,"median":-1.832728,"eighty":-1.317621,"marketCap":14227727},{"date":"2023-09-22","current":-0.943498,"twenty":-2.157356,"median":-1.828939,"eighty":-1.314844,"marketCap":9309500},{"date":"2023-09-29","current":-1.032507,"twenty":-2.13103,"median":-1.825151,"eighty":-1.294017,"marketCap":10187755},{"date":"2023-10-06","current":-1.201625,"twenty":-2.129337,"median":-1.825151,"eighty":-1.278744,"marketCap":11856439},{"date":"2023-10-13","current":-1.183912,"twenty":-2.127644,"median":-1.825151,"eighty":-1.266525,"marketCap":11681667},{"date":"2023-10-20","current":-1.201625,"twenty":-2.127644,"median":-1.818844,"eighty":-1.249588,"marketCap":11856439},{"date":"2023-10-27","current":-1.326238,"twenty":-2.127644,"median":-1.816544,"eighty":-1.252365,"marketCap":13085996},{"date":"2023-11-03","current":-1.148219,"twenty":-2.126306,"median":-1.810749,"eighty":-1.249588,"marketCap":11329486},{"date":"2023-11-10","current":-1.317337,"twenty":-2.123935,"median":-1.80496,"eighty":-1.242173,"marketCap":12998171},{"date":"2023-11-17","current":-1.735051,"twenty":-2.120976,"median":-1.80496,"eighty":-1.249588,"marketCap":12559043},{"date":"2023-11-24","current":-1.837849,"twenty":-2.117339,"median":-1.80496,"eighty":-1.249588,"marketCap":13303140},{"date":"2023-12-01","current":-2.179164,"twenty":-2.117339,"median":-1.806544,"eighty":-1.249588,"marketCap":15773723},{"date":"2023-12-08","current":-1.995379,"twenty":-2.117339,"median":-1.813341,"eighty":-1.249588,"marketCap":14443409},{"date":"2023-12-15","current":-1.890359,"twenty":-2.11519,"median":-1.816544,"eighty":-1.250976,"marketCap":13683229},{"date":"2023-12-22","current":-1.916614,"twenty":-2.106539,"median":-1.824721,"eighty":-1.256675,"marketCap":13873274},{"date":"2023-12-29","current":-2.192291,"twenty":-2.117284,"median":-1.825151,"eighty":-1.257111,"marketCap":15868745},{"date":"2024-01-05","current":-1.916614,"twenty":-2.117321,"median":-1.825151,"eighty":-1.259926,"marketCap":13873274},{"date":"2024-01-12","current":-2.094491,"twenty":-2.113114,"median":-1.825151,"eighty":-1.266525,"marketCap":15160828},{"date":"2024-01-19","current":-2.01507,"twenty":-2.106539,"median":-1.832728,"eighty":-1.270414,"marketCap":14585943},{"date":"2024-01-26","current":-2.080707,"twenty":-2.104197,"median":-1.835522,"eighty":-1.271503,"marketCap":15061055},{"date":"2024-02-02","current":-2.021634,"twenty":-2.104197,"median":-1.837849,"eighty":-1.277052,"marketCap":14633454},{"date":"2024-02-09","current":-2.061016,"twenty":-2.100399,"median":-1.837849,"eighty":-1.281982,"marketCap":14918521},{"date":"2024-02-16","current":-1.982251,"twenty":-2.100399,"median":-1.839671,"eighty":-1.282958,"marketCap":14348386},{"date":"2024-02-23","current":-1.864104,"twenty":-2.100399,"median":-1.844413,"eighty":-1.284298,"marketCap":13493185},{"date":"2024-03-01","current":-3.045578,"twenty":-2.106887,"median":-1.846747,"eighty":-1.29124,"marketCap":22045203},{"date":"2024-03-08","current":-2.034761,"twenty":-2.117357,"median":-1.850976,"eighty":-1.299535,"marketCap":14728476},{"date":"2024-03-15","current":-2.799727,"twenty":-2.127644,"median":-1.85621,"eighty":-1.299535,"marketCap":20265625},{"date":"2024-03-22","current":-3.226804,"twenty":-2.174343,"median":-1.857797,"eighty":-1.305125,"marketCap":23356992},{"date":"2024-03-28","current":-3.290074,"twenty":-2.197195,"median":-1.866632,"eighty":-1.310679,"marketCap":23814972},{"date":"2024-04-05","current":-3.721769,"twenty":-2.225304,"median":-1.875692,"eighty":-1.312067,"marketCap":29539725},{"date":"2024-04-12","current":-3.409184,"twenty":-2.252484,"median":-1.878554,"eighty":-1.316283,"marketCap":27058731},{"date":"2024-04-19","current":-4.047499,"twenty":-2.337419,"median":-1.887373,"eighty":-1.317337,"marketCap":32125047},{"date":"2024-04-26","current":-3.496227,"twenty":-2.358916,"median":-1.888933,"eighty":-1.318675,"marketCap":27749593},{"date":"2024-05-03","current":-3.322141,"twenty":-2.371393,"median":-1.894051,"eighty":-1.319009,"marketCap":26367870},{"date":"2024-05-10","current":-2.930448,"twenty":-2.380496,"median":-1.903486,"eighty":-1.324792,"marketCap":23258995},{"date":"2024-05-17","current":-3.371987,"twenty":-2.422355,"median":-1.908084,"eighty":-1.34267,"marketCap":28210167},{"date":"2024-05-24","current":-3.38575,"twenty":-2.456329,"median":-1.916614,"eighty":-1.363439,"marketCap":28325310},{"date":"2024-05-31","current":-3.330698,"twenty":-2.475014,"median":-1.920868,"eighty":-1.369487,"marketCap":27864736},{"date":"2024-06-07","current":-3.126113,"twenty":-2.555469,"median":-1.925914,"eighty":-1.381356,"marketCap":26462608},{"date":"2024-06-14","current":-2.936249,"twenty":-2.635174,"median":-1.928853,"eighty":-1.388459,"marketCap":24564761},{"date":"2024-06-21","current":-2.591791,"twenty":-2.696804,"median":-1.932424,"eighty":-1.389875,"marketCap":21683018},{"date":"2024-06-28","current":-2.968019,"twenty":-2.720158,"median":-1.935984,"eighty":-1.392624,"marketCap":24830553},{"date":"2024-07-05","current":-3.023756,"twenty":-2.794585,"median":-1.942395,"eighty":-1.395373,"marketCap":25296855},{"date":"2024-07-12","current":-3.399984,"twenty":-2.87532,"median":-1.950745,"eighty":-1.39815,"marketCap":28444390},{"date":"2024-07-15","current":-3.567196,"twenty":-2.892729,"median":-1.953371,"eighty":-1.399538,"marketCap":29843294},{"date":"2024-08-02","current":-3.316378,"twenty":-2.907236,"median":-1.955996,"eighty":-1.400927,"marketCap":27744938},{"date":"2024-08-09","current":-2.533442,"twenty":-2.889827,"median":-1.959964,"eighty":-1.402315,"marketCap":21194865},{"date":"2024-08-16","current":-2.384759,"twenty":-2.863715,"median":-1.969124,"eighty":-1.407869,"marketCap":20833589},{"date":"2024-08-23","current":-2.678705,"twenty":-2.829511,"median":-1.969729,"eighty":-1.414811,"marketCap":23401547},{"date":"2024-08-30","current":-2.393496,"twenty":-2.820363,"median":-1.976948,"eighty":-1.421809,"marketCap":20909923},{"date":"2024-09-06","current":-2.138705,"twenty":-2.807777,"median":-1.982251,"eighty":-1.427335,"marketCap":18684028},{"date":"2024-09-13","current":-2.547915,"twenty":-2.792014,"median":-1.989241,"eighty":-1.434249,"marketCap":22258950},{"date":"2024-09-20","current":-3.103824,"twenty":-2.814197,"median":-1.994133,"eighty":-1.43998,"marketCap":27115448},{"date":"2024-09-27","current":-3.042056,"twenty":-2.869518,"median":-1.995379,"eighty":-1.455656,"marketCap":26575837},{"date":"2024-10-04","current":-2.887637,"twenty":-2.923292,"median":-1.995379,"eighty":-1.483558,"marketCap":25226810},{"date":"2024-10-11","current":-2.980289,"twenty":-2.932768,"median":-2.002272,"eighty":-1.506321,"marketCap":26036226},{"date":"2024-10-18","current":-3.289127,"twenty":-2.972927,"median":-2.01507,"eighty":-1.523838,"marketCap":28734281},{"date":"2024-10-25","current":-1.992007,"twenty":-2.956851,"median":-2.021634,"eighty":-1.532989,"marketCap":17402452},{"date":"2024-10-31","current":-2.115542,"twenty":-2.944143,"median":-2.021634,"eighty":-1.536549,"marketCap":18481674},{"date":"2024-11-08","current":-2.038332,"twenty":-2.933929,"median":-2.021634,"eighty":-1.53986,"marketCap":17807160},{"date":"2024-11-15","current":-2.053774,"twenty":-2.925677,"median":-2.02191,"eighty":-1.53986,"marketCap":17942063},{"date":"2024-11-22","current":-2.278807,"twenty":-2.911686,"median":-2.025706,"eighty":-1.540379,"marketCap":19247024},{"date":"2024-11-29","current":-2.241903,"twenty":-2.898674,"median":-2.034761,"eighty":-1.544459,"marketCap":18935331},{"date":"2024-12-06","current":-1.946673,"twenty":-2.887637,"median":-2.034498,"eighty":-1.559915,"marketCap":16441789},{"date":"2024-12-13","current":-1.796844,"twenty":-2.887495,"median":-2.025706,"eighty":-1.574592,"marketCap":15176317},{"date":"2024-12-20","current":-2.177321,"twenty":-2.881123,"median":-2.023021,"eighty":-1.597881,"marketCap":18389869},{"date":"2024-12-27","current":-1.752928,"twenty":-2.857912,"median":-2.021634,"eighty":-1.600387,"marketCap":14805403},{"date":"2025-01-03","current":-1.734661,"twenty":-2.856986,"median":-2.021634,"eighty":-1.60117,"marketCap":14651115},{"date":"2025-01-10","current":-1.699602,"twenty":-2.836148,"median":-2.018352,"eighty":-1.601847,"marketCap":14355007},{"date":"2025-01-17","current":-1.335731,"twenty":-2.820875,"median":-2.007448,"eighty":-1.564421,"marketCap":11281717},{"date":"2025-01-24","current":-1.163022,"twenty":-2.816082,"median":-2.001445,"eighty":-1.53986,"marketCap":9822995},{"date":"2025-01-31","current":-1.429282,"twenty":-2.810428,"median":-1.995379,"eighty":-1.520278,"marketCap":12071858},{"date":"2025-02-07","current":-1.549958,"twenty":-2.806148,"median":-1.995379,"eighty":-1.476717,"marketCap":13091093},{"date":"2025-02-14","current":-1.47615,"twenty":-2.794585,"median":-1.993467,"eighty":-1.461865,"marketCap":12467708},{"date":"2025-02-21","current":-1.494602,"twenty":-2.780852,"median":-1.992007,"eighty":-1.460888,"marketCap":12623554},{"date":"2025-02-28","current":-0.963926,"twenty":-2.75515,"median":-1.991074,"eighty":-1.443623,"marketCap":8141413},{"date":"2025-03-07","current":-0.701171,"twenty":-2.745155,"median":-1.982251,"eighty":-1.43747,"marketCap":5922161},{"date":"2025-03-14","current":-0.653934,"twenty":-2.729886,"median":-1.976948,"eighty":-1.424425,"marketCap":5523194},{"date":"2025-03-21","current":-0.517575,"twenty":-2.72248,"median":-1.97152,"eighty":-1.402315,"marketCap":4371490},{"date":"2025-03-28","current":-0.499123,"twenty":-2.711125,"median":-1.969124,"eighty":-1.395373,"marketCap":4215643},{"date":"2025-04-04","current":-1.208694,"twenty":-2.703877,"median":-1.960774,"eighty":-1.389313,"marketCap":10926387},{"date":"2025-04-11","current":-1.109488,"twenty":-2.699246,"median":-1.959964,"eighty":-1.373373,"marketCap":10029580},{"date":"2025-04-17","current":-0.930218,"twenty":-2.686893,"median":-1.950745,"eighty":-1.346778,"marketCap":8409017},{"date":"2025-04-25","current":-1.014207,"twenty":-2.686893,"median":-1.946121,"eighty":-1.319009,"marketCap":9168264},{"date":"2025-05-02","current":-0.940915,"twenty":-2.678705,"median":-1.937447,"eighty":-1.312067,"marketCap":8505714}],"updateTime":1746454440166}}}